Follow up of women with borderline cervical smears as defined by national guidelines

Mark K Heatley

Abstract

Aim—To determine the proportion of women with abnormalities in cervical smears corresponding to borderline nuclear change, as defined by national guidelines, which return to normal or persist as cytological or histological abnormalities.

Methods—313 women with borderline nuclear change diagnosed by a single pathologist using the national criteria were followed up for up to two years.

Results—On initial follow up, 45% of women had a negative smear or biopsy, 46.5% had a low grade cytological or histological abnormality, and 8.5% had a high grade abnormality. Of 81 patients in whom a second follow up smear or biopsy was available, 47% had no detectable abnormality, 38.5% had low grade lesion, and 14.5% had a high grade lesion. In total, 32 patients (10.2%) had a high grade lesion (defined as moderate or severe dyskaryosis on smear or CINII or CINIII on biopsy) on at least one follow up sample.

Conclusions—The results support the use of the national criteria defining borderline nuclear change in identifying women at increased risk of developing a high grade cervical intraepithelial neoplasia, as identified histologically or cytologically, and highlight the importance of follow up in these patients.

Keywords: cervix; cervical intraepithelial neoplasia; cytology

Long term follow up of women with borderline nuclear changes on routine cytological screening has shown that a substantial proportion developed high grade dyskaryosis. More recently the British Society for Clinical Cytology and the Royal College of Pathologists cooperated to produce a series of guidelines defining borderline nuclear changes in cervical smears and provided illustrations to assist in their identification. The appropriateness of these guidelines has been discussed publicly.

This paper provides details of the follow up of 313 women who have had borderline nuclear changes in their cervical smears diagnosed by a single pathologist using the nationally suggested criteria.

Methods

The cases had been submitted to the Department of pathology at the Jessop Hospital for Women, Sheffield, and the department of cellular pathology at the Taunton and Somerset NHS Trust. Following primary screening and checking by cytoscreeners and medical laboratory scientific officers as detailed in the relevant departmental protocols, all the slides were examined by a single pathologist. The slides were completely rescreened and the features in the abnormal cells compared with diagnostic criteria provided by the working party. Where possible, a direct comparison with one of the images provided by the borderline booklet was made. Only cases in which the changes were located in squamous epithelial cells were studied.

Follow up, limited to up to two years after the index smear, was obtained from the cytopathology and histopathology records of the two departments, other pathology departments, from the patients' general practitioners and from the appropriate commissioning bodies in the relevant health authorities. The criteria used for defining these cytopathological and histopathological abnormalities has been described previously. Post-treatment smears in those patients who received definitive therapy at their first review were not included in these data.

Results

Borderline nuclear changes were identified in 353 patients. No follow up was available in 40 patients. Of the remaining 313 patients, 45% had a negative smear or biopsy on initial follow up, 46.5% had a low grade abnormality (that is, a borderline or mildly dyskaryotic smear or CINI on biopsy) on repeat smear or biopsy, and 8.5% had a high grade abnormality (moderate or severe dyskaryosis on smear or CINII or CINIII on biopsy) on repeat smear or biopsy (table 1). In 232 cases no further follow up was available. Thirty five per cent of these had had a negative smear on first review, 56% had had mild dyskaryosis or CINI, and 9% had had moderate or severe dyskaryosis or CINII or CINIII. In 81 cases a second repeat smear or biopsy was available. In 47% of these cases there was no abnormality detected, 38.5% had a low grade abnormality, and 14.5% had a high grade abnormality on this second repeat smear or biopsy (table 1).

Discussion

There is a greater chance that women with borderline smears will be found subsequently to have high grade cervical abnormalities than
Table 1

<table>
<thead>
<tr>
<th>Results of cytological follow up</th>
<th>Dyskaryosis</th>
<th>Results of histological follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Negative</td>
<td>BNC</td>
</tr>
<tr>
<td>First review</td>
<td>117/36%</td>
<td>55/18%</td>
</tr>
<tr>
<td>Second review</td>
<td>31/38%</td>
<td>5/6%</td>
</tr>
</tbody>
</table>

BNC, borderline nuclear change; CIN, cervical intraepithelial neoplasia.

Table 2

<table>
<thead>
<tr>
<th>Follow up with cytology (dyskaryosis)</th>
<th>Follow up with histology</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>First review</td>
</tr>
<tr>
<td></td>
<td>Negative BNC Mild Moderate Severe</td>
</tr>
<tr>
<td></td>
<td>30/2/0/1/0</td>
</tr>
<tr>
<td>Cytology</td>
<td>30/2/0/1/0</td>
</tr>
<tr>
<td>BNC</td>
<td>0/3/0/0/1</td>
</tr>
<tr>
<td>Dyskaryosis</td>
<td>1/0/2/0/0</td>
</tr>
<tr>
<td>Mild</td>
<td>1/0/2/0/0</td>
</tr>
<tr>
<td>Moderate</td>
<td>0/0/0/0/0</td>
</tr>
<tr>
<td>Histology</td>
<td>0/0/0/0/0</td>
</tr>
<tr>
<td>CINI</td>
<td>31/5/2/1/1</td>
</tr>
<tr>
<td>Total</td>
<td>31/5/2/1/1</td>
</tr>
</tbody>
</table>

BNC, borderline nuclear change; CIN, cervical intraepithelial neoplasia.

those with reactive changes. This study indicates that 10.2% of women developed a high grade dyskaryosis or CIN lesion within two years of having a borderline smear. Hirschowitz et al found that 22.4% of women with borderline cytological changes had a smear test showing high grade dyskaryosis which developed between 13 and 106 months after the index smear. Fifty per cent of these women, or 11.2% of their total study group, developed their high grade lesion within 34 months. The frequency with which a high grade lesion was identified after a borderline smear was therefore similar in the two studies. This study, however, is the first to use the national guidelines to define the borderline smears.

The presence of a low grade lesion in seven women and of a high grade lesion in three women who had a negative smear following the initial borderline diagnosis (table 2) supports the current policy of requiring that a women has at least two negative smears before she is returned to routine follow up. In 20 women on first review (table 2) the smear showed borderline nuclear change and of these only one had a subsequent negative biopsy, the remainder showing low grade abnormality (16 cases) or high grade abnormality (three cases). This highlights the importance of continued follow up in women with a persistent borderline abnormality. Nine women had mild dyskaryosis or CINI on smear or biopsy as an initial investigation on first review (table 2). One of these patients had a subsequent negative smear and the remaining eight women showed no evidence of progression or regression, highlighting the relative stability of this lesion.11-12

This follow up study confirms the previous suggestion that borderline smears are associated with the subsequent diagnosis of high grade cervical lesions in about one tenth of women in the short term, possibly because in some cases they were underrepresented on the index smear. It provides evidence to support the validity of the borderline document and justifies the careful follow up of women with borderline smears which has been recommended nationally.

I should like to thank Dr Jerry O'Sullivan, St Richards Hospital, Chichester for reading the manuscript, and also Mrs Jill Gosney for secretarial assistance.

Follow up of women with borderline cervical smears as defined by national guidelines.

M K Heatley

doi: 10.1136/jcp.52.10.787

Updated information and services can be found at:
http://jcp.bmj.com/content/52/10/787

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/